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Favorable response of advanced superior sulcus non-small
cell lung carcinoma to gefitinib for 11 years complicated by
interval development of small cell carcinoma of the lung
Mark H Cooper, MD, PhD1, Tracy Dobbs, MD2, Yehuda Z Lebowicz, MD1

ABSTRACT
Gefitinib is a medication that was originally developed as an epidermal growth factor
receptor (EGFR) blocker. It has been used to treat non-small cell lung cancer with
varying success. We describe a patient who presented with Pancoasts syndrome and
was deemed surgically unresectable. He had limited success with chemotherapy and
radiation but had an excellent response to the medication gefitinib. The patient was
disease free for several years and after eleven years of follow up with CT scans, a PET CT
showed an isolated area of FDG avidity which on biopsy was small cell carcinoma of the
lung. The patient had been maintained continually on gefitinib (Iressa) for eleven years.
Gefitinib treatment and continuing EGFR blockade invariably result in resistance to the
medication and ultimate relapse. However in the present case, presumed sensitivity of
the original tumor for a prolonged time period was noted, with development of either
a new, small cell lung cancer, or histologic transformation. Similar cases have described
this phenomenon of epithelial cancers treated with tyrosine kinase inhibitor blockade
and development of small cell lung cancer; however, our case is unusual in that this
transformation is observed over an eleven year time span.
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INTRODUCTION
Lung cancer is a leading cause of mortality
worldwide. Overall survival has lagged behind the
improved survival seen with breast cancer, prostate
cancer and colorectal cancer patients.1 A significant
number of patients with lung cancer present at an
advanced stage. CT screening aims to find patients
with disease much earlier in their natural history.
The treatment of advanced non-small cell carcinoma
of the lung with chemotherapy and/or radiation has
been the mainstay of therapy. Newer medications
with fewer side effects aim to improve survival, while
preserving quality of life. Current therapies have
focused on different inhibitors of the components
of tumor biology. Monoclonal antibodies, such as
Bevacizumab, can block angiogenesis by inhibiting
vascular endothelial growth factor A. Epidermal
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growth factor receptor blockers, in the form of
tyrosine kinase inhibitors, have been developed
to block the EGFR ligand. EGFR can be activated
by epidermal growth factor and TGF alpha. EGFR
plays an important role in cell proliferation, and
mutations that activate this pathway promote cell
proliferation and survival. Examples of agents that
block EGFR include erlotinib (Tarceva), gefitinib
(Iressa), afatinib and oimertinib.2 Erlotinib has been
shown to be effective in the treatment of tumors
with EGFR activity translating into improved survival.3
Unfortunately, most patients ultimately develop
resistance.
The biology of resistance mechanisms of lung cancer
to medical therapy is complex and is still poorly
understood. The consequences of prolonged EGFR
blockade are unknown, but in most cases relapse
of the original tumor occurs.4 We describe a case
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of a patient with advanced right sided superior
sulcus (Pancoast tumor) of the lung who had a poor
response to chemotherapy and radiation. The patient
responded extremely well to gefitinib. After ten years
of CT surveillance the patient developed an isolated
area of biopsy proven small cell lung cancer in the
bronchus intermedius and right middle lobe. The
new site of FDG uptake was different when compared
to the patient’s initial tumor presentation site. He
is currently receiving systemic chemotherapy and
radiation treatment. Previous studies have reviewed
the clinical characteristics of transformed small
cell lung cancer and whether this represents a new
subtype of small cell carcinoma.
CASE REPORT
A 55 year old Caucasian male with a prior smoking
history presented twelve years ago with symptoms
attributed to Pancoast syndrome. Symptoms
included neuropathy due to locally advanced
malignancy. Biopsy revealed an undifferentiated
non-small cell lung carcinoma
without typical squamous
although with some glandular
differentiation. Radiologically,
the tumor was locally invasive
into the surrounding mediastinal
structures and the patient was
deemed not a surgical candidate.
He was initially treated with
conventional chemotherapy and
radiation but had a relatively
poor response radiologically
and clinically. He was then
commenced on the medication
gefitinib in April 2004 and
was noted to have a sustained
response to therapy. There was
interval resolution of tumor
mass as assessed by follow up
CT scans. No genetic testing
was available at that time, and
his mutation status was unknown. The patient had
ceased to smoke at the time of his original lung
cancer diagnosis twelve years ago.
His dramatic radiologic and clinical response perhaps
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implied that he very likely had an EGFR activating
mutation. He was maintained on gefitinib for eleven
years in remission, and maintained an excellent
performance status. Past medical history included
myocardial infarction and a left nephrectomy. He
had no occupational exposure. The patient had
never used oxygen at home and was able to climb
a flight of stairs with relative ease. Blood tests were
normal.
As part of ongoing surveillance, a chest CT
scan prompted a PET/CT scan which showed a
new area of FDG avidity, situated near the right
bronchus intermedius of approximately 12 x 17
mm in size (Figure 1). This was concerning for
tumor recurrence. The new FDG avid area was in a
different site as compared to the patient’s original
tumor site. There were no other areas of concern.
Physical examination showed a thin Caucasian
male with normal vital signs. He had no palpable
lymphadenopathy, and clinical examination of
the chest revealed no abnormality. Bronchoscopy

FIGURE 1: Pet/CT scan from 2014 in a 55 year old
Caucasian male with a history of Pancoasts syndrome and
a complete response to Iressa. There is an FDG avid right
hilar mass confirmed on bronchoscopic biopsy to be small
cell carcinoma. The patient is receiving treatment with
radiation and chemotherapy.
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was scheduled with the intent of obtaining a
transbronchial needle aspiration biopsy. Partially
occlusive endobronchial disease was found in and
around the middle lobe bronchus and conventional
biopsies were obtained. (Figure 2). Histopathology
showed small cell carcinoma. The patient was
commenced on conventional chemotherapy and
radiation for small cell lung cancer. He continues to
have good performance status.

FIGURE 2: Bronchoscopic view of an endobronchial lesion
encountered during the bronchoscopic procedure in a
55 year old Caucasian male with a history of Pancoasts
syndrome that responded to Iressa. The Olympus bronchoscope finds endobronchial disease that is partially
occlusive in the right middle lobe. Biopsies showed small
cell lung cancer. The patient is undergoing treatment for
localized small cell lung cancer.

DISCUSSION
Gefitinib is an EGFR tyrosine kinase receptor blocker.
It was the first generation of EGFR blockers used to
treat patients with advanced non-small cell lung
cancer who had failed chemotherapy.3 Although
NSCLC is the most common type of lung cancer,
EGFR gene mutations occur in about 10% of NSCLC
tumors, as assessed by the National Cancer Institute.
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Gefitinib is intended for the treatment of patients
whose tumors express the most common types of
EGFR mutations in NSCLC tumors: exon 19 deletions
or exon 21 L858R substitution gene mutations. The
diagnostic test, known as the therascreen EGFR RGQ
PCR Kit, identifies patients who have these very
specific EGFR gene mutations. The US Food and Drug
Administration announced in 2015 the approval
of gefitinib for first-line treatment of patients with
metastatic non–small cell lung cancer (NSCLC) whose
tumors contain specific types of
epidermal growth factor receptor
(EGFR) gene mutations. The new
approval represented a reversal
of an earlier decision for the drug
in the United States.
Gefitinib originally received
accelerated approval in 2003
for the treatment of patients
with advanced NSCLC after
progression on platinum
chemotherapy. However, the
drug was withdrawn from the
market after confirmatory trials
failed to verify clinical benefit;
at that time, it was not known
that the drug effectiveness was
limited to mutation-specific
patients.5
The FDA approval of gefitinib was
based on results from a multicenter, single-group
clinical trial of 106 patients with metastatic NSCLC
that was EGFR mutation–positive and previously
untreated. After treatment with gefitinib (250
mg once daily), 50% of patients had an objective
response. The response rates were similar in patients
whether their tumors had EGFR exon 19 deletions or
exon 21 L858R substitution mutations. These results
are complimented by another clinical trial, in which
186 patients had metastatic, EGFR-positive NSCLC
and received first-line treatment with gefitinib. The
patients randomly assigned to receive gefitinib
had better progression-free survival than patients
receiving standard chemotherapy (such as four to six
cycles of carboplatin/paclitaxel).6 Thus, the current
approval is for a patient population, notably EGFR
mutation–positive patients who were previously
untreated, which is different than that of the 2003
approval.
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In clinical trials, groups of patients with stages three
and four lung cancer receiving gefitinib experienced
a significantly longer period of progression-free
survival (9.2 months) compared with patients who
received platinum/Taxanes (6.3 months). Toxicity
was tolerable for both groups and grade 3/4 adverse
events were rare. The patient in the present report
had a very favorable response to gefitinib when
conventional chemotherapy had been relatively
unsuccessful. The patient in the present report was
not tested for genetic mutations and had a diagnosis
of undifferentiated non-small cell carcinoma. State
of the art treatment for advanced unresectable
non-small cell lung cancer includes DNA testing to
identify tumors that are EGFR positive. Treatment
is usually initiated with newer EGFR blockers such
as erlotinib. Response rates of patients with EGFR
positive tumors treated with erlotinib are high.
Patients with adenocarcinoma are more likely to
exhibit the EGFR, although even these patients are in
a minority group.
Side effects of gefitinib include nausea, emesis,
reduced appetite, rash itching, acne and weakness.
Gefitinib may cause serious adverse effects
including interstitial lung disease, liver damage,
gastrointestinal perforation, severe diarrhea, and
ocular disorders. The most common adverse effects
are diarrhea and skin reactions (including rash, acne,
dry skin, and pruritus).
There is documented evidence of development
of small cell lung cancer in patients treated with
tyrosine kinase inhibitors.7,8 Our patient had been
treated for more than ten years with gefitinib,
which is a much longer time period than is
documented in other studies for the development
of small cell lung cancer that. Previous authors
have suggested mechanisms that may account for
the switch between non-small cell lung cancer of
epithelial origin and small cell lung cancer.7 These
authors’ hypotheses include the possibility of dedifferentiation of a well-defined epithelial cancer
to a small cell lung cancer or a second possibility,
such as the co-existence of two succinct progenitor
types of cell from epithelial and neuroendocrine
origins, these cells being present at the initial cancer
presentation. Yet a third mechanism could be the
existence of both types of established tumor but
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with small cell lung cancer being present in very
small amounts that can be missed through sampling
error. Taken together, it is our view that there is a
loss of epithelial cellular differentiation, by blockade
with tyrosine kinase inhibitors. This may allow the
cells to seek another pathway of differentiation
to a different cell type. This leads to histologic
transformation.
Studies in vitro have shown that chronically adapted
non-small cell lung cancer cell lines have induction
of fibroblast growth factor mRNA and protein.9
These in vitro studies suggest that other proteins
that have adapted in cells as a result of chronic
stimulation do occur, and may therefore become
subsequent targets for the development of other
novel medications to target treatment.
There is relatively new data regarding lung
cancer screening. Current guidelines include
recommendations for patients between ages
55 to 80 years old with a 30 pack year smoking
history. There is a twenty percent improvement
in survival in the CT scan screened patient cohort
compared to those followed by chest X ray. The
National Comprehensive Cancer Network (NCCN)
guidelines also suggest continued follow up with
CT scans for patients with lung cancer to monitor
their responses to treatment. We support the idea
of continued follow up, since our patient in this
report has developed either another primary tumor
albeit of a different histological type or histologic
transformation of the original disease. In this
present patient, development of new malignancy
may be related to those risk factors that initiated
the original tumor. The other possibilities include a
loss of effectiveness of gefitinib and/or interference
with cellular mechanisms that may protect the
body against subsequent tumor initiation. For each
interaction with a receptor, there is another effect on
the cell that will trigger another series of molecular
mechanisms that affects the cell in a different way.
Lung cancer patients with metastatic disease should
be followed every three to six months with a CT
scan. Most patients treated with EGFR blockade
therapy are treated between one to two years before
they relapse. It is uncommon for patients to be
maintained on EGFR blockade for eleven years.
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